Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Anderson Hoagland & Co.

Anderson Hoagland & Co. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 84.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 535 shares of the biopharmaceutical company’s stock after selling 2,854 shares during the period. Anderson Hoagland & Co.’s holdings in Regeneron Pharmaceuticals were worth $365,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Linden Thomas Advisory Services LLC grew its holdings in shares of Regeneron Pharmaceuticals by 8.6% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 3,055 shares of the biopharmaceutical company’s stock worth $2,176,000 after purchasing an additional 241 shares during the period. Exchange Traded Concepts LLC raised its position in Regeneron Pharmaceuticals by 53.2% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,159 shares of the biopharmaceutical company’s stock valued at $4,387,000 after purchasing an additional 2,139 shares during the period. Greater Midwest Financial Group LLC lifted its stake in Regeneron Pharmaceuticals by 23.3% during the fourth quarter. Greater Midwest Financial Group LLC now owns 3,108 shares of the biopharmaceutical company’s stock worth $2,214,000 after purchasing an additional 588 shares in the last quarter. Brighton Jones LLC boosted its position in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the period. Finally, Montecito Bank & Trust grew its stake in shares of Regeneron Pharmaceuticals by 12.4% in the fourth quarter. Montecito Bank & Trust now owns 1,252 shares of the biopharmaceutical company’s stock valued at $892,000 after buying an additional 138 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on REGN shares. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Citigroup reduced their price objective on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 14th. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Finally, Bank of America reaffirmed an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $675.79 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market cap of $74.26 billion, a P/E ratio of 16.72, a P/E/G ratio of 1.59 and a beta of 0.10. The stock has a 50 day moving average of $727.19 and a two-hundred day moving average of $937.77. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.